Login / Signup

New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle.

Maliki AnkavayClaire MontpellierIbrahim M SayedJean-Michel SaliouCzeslaw WychowskiLaure SaasSandrine DuvetCécile-Marie Aliouat-DenisRayan FarhatValentin de Masson d'AutumePhilip MeulemanJean DubuissonLaurence Cocquerel
Published in: Scientific reports (2019)
Hepatitis E Virus (HEV) genome encodes three proteins including the ORF2 capsid protein. Recently, we demonstrated that HEV produces three different forms of ORF2: (i) the ORF2i form (infectious ORF2) which is the component of infectious particles, (ii) the secreted ORF2g (glycosylated ORF2) and ORF2c (cleaved ORF2) forms that are not associated with infectious particles, but are the major antigens in HEV-infected patient sera. The ORF2 protein sequence contains three highly conserved potential N-glycosylation sites (N1, N2 and N3). The status and biological relevance of ORF2 N-glycosylation in HEV lifecycle remain to be elucidated. Here, we generated and extensively characterized a series of ORF2 mutants in which the three N-glycosylation sites were mutated individually or in combination. We demonstrated that the ORF2g/c protein is N-glycosylated on N1 and N3 sites but not on the N2 site. We showed that N-glycosylation of ORF2 protein does not play any role in replication and assembly of infectious HEV particles. We found that glycosylated ORF2g/c forms are very stable proteins which are targeted by patient antibodies. We also demonstrated that the ORF2i protein is translocated into the nucleus of infected cells. Hence, our study led to new insights into the molecular mechanisms of ORF2 expression.
Keyphrases
  • protein protein
  • amino acid
  • dna methylation
  • signaling pathway
  • drug delivery
  • cell death
  • induced apoptosis
  • cancer therapy
  • pi k akt